The Changes in End Expiratory Lung Impedence Measured by EIT and End Expiratory Lung Volume Measured by Passive Expiratory in Controlled Mechanical Ventilated Exacerbation COPD Patients

COPD Clinical Trial

Official title:

The Relevance and Consistency Study of Changes in End Expiratory Lung Impedence Measured by EIT and End Expiratory Lung Volume Measured by Passive Expiratory in Controlled Mechanical Ventilated Exacerbation COPD Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05585060
• Other study ID #: FAHGuangzhou_20220711
• Status: Recruiting
• Phase: N/A
• Start date: September 13, 2022
• Est. completion date: October 8, 2023

Study information

• Verified date: November 2022
• Source: The First Affiliated Hospital of Guangzhou Medical University
• Contact: Wei Fu, MD
• Phone: +8602083062882
• Email: hooray_009[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The pathophysiological characteristics of respiratory failure on exacerbation of chronic pulmonary obstructive disease are the rapid deteriorate of respiratory symptoms, combined with aggravated flow limitation, gas trapping, dynamic pulmonary hyperinflation (DPH), therefore the intrinsic PEEP (PEEPi) increases. It is worthwhile to explore bedside methods to quantify the changes in dynamic pulmonary hyperinflation to guide safe and effective mechanical ventilation in airflow limited patients.

Description:

The study hypothesizes that the electrical impedence tomography (EIT) measured the changes of end expiratory lung impedence (△EELI） could accurately predict the changes of end expiratory lung volume （△EELV） measured by passive expiratory in controlled mechanical ventilated exacerbation COPD patients. The research intended to conduct a research to explore the relationship between △EELI and △EELV induced by external PEEP changes in ventilated exacerbation COPD patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: October 8, 2023
• Est. primary completion date: October 8, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 35 Years to 80 Years

Eligibility

Inclusion Criteria:

• 2022.7-2023.1 exacerbation COPD invasive ventilated patients admitted to the first affiliated Guangzhou medical university; 35 to 80 years old; in stable condition judged by clinicians

Exclusion Criteria:

• SpO2<88%; instable hemodynamic (MAP<65mmHg;Norepinephrine> 0.1ug/kg.min); pregnancy; 4 hour intravenous diuretics use before research; chest deformity and trauma, subpleural pulmonary bulla; implanted electronic devices(cardiac pacemaker, implantable cardioversion defibrillator,ect); tumour or other organ dysfunction; refuse to signature the informed consent

Related Conditions & MeSH terms

• COPD

Intervention

Diagnostic Test:
• the changes of end expiratory lung impedence
the changes of end expiratory lung impedence measured by EIT
• the changes of end expiratory lung volume
the changes of end expiratory lung volume measured by apnea method

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Guangzhou Medical	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
The First Affiliated Hospital of Guangzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the changes of end expiratory lung volume	measured by EIT and IC maneuver	10 minutes
Secondary	intrinsic PEEP	measured by Esophageal balloon catheters	10 minutes